JP2005506524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506524A5 JP2005506524A5 JP2002579991A JP2002579991A JP2005506524A5 JP 2005506524 A5 JP2005506524 A5 JP 2005506524A5 JP 2002579991 A JP2002579991 A JP 2002579991A JP 2002579991 A JP2002579991 A JP 2002579991A JP 2005506524 A5 JP2005506524 A5 JP 2005506524A5
- Authority
- JP
- Japan
- Prior art keywords
- subunit
- integrin
- activation
- agent
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 8
- 102000006495 integrins Human genes 0.000 claims 7
- 108010044426 integrins Proteins 0.000 claims 7
- 230000004913 activation Effects 0.000 claims 6
- 230000033115 angiogenesis Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 108700008625 Reporter Genes Proteins 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 230000006427 angiogenic response Effects 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000001962 electrophoresis Methods 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28151201P | 2001-04-04 | 2001-04-04 | |
| PCT/US2002/010501 WO2002081627A2 (en) | 2001-04-04 | 2002-04-03 | Methods of screening and using inhibitors of angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506524A JP2005506524A (ja) | 2005-03-03 |
| JP2005506524A5 true JP2005506524A5 (enExample) | 2006-01-05 |
Family
ID=23077607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002579991A Withdrawn JP2005506524A (ja) | 2001-04-04 | 2002-04-03 | 血管新生の阻害剤をスクリーニングおよび使用する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20030171271A1 (enExample) |
| EP (1) | EP1393075A4 (enExample) |
| JP (1) | JP2005506524A (enExample) |
| CA (1) | CA2443378A1 (enExample) |
| WO (1) | WO2002081627A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8574827B2 (en) | 2002-10-29 | 2013-11-05 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
| WO2005080984A1 (en) * | 2004-02-17 | 2005-09-01 | Rigel Pharmaceuticals, Incorporated | Modulators of angiogenesis and tumorigenesis |
| HRP20130782T1 (en) * | 2004-04-02 | 2013-09-30 | The Regents Of The University Of California, Office Of Technology Transfer | Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| EP2456460A4 (en) | 2009-07-24 | 2013-02-20 | Univ California | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022948A (en) * | 1996-09-17 | 2000-02-08 | Washington University | Method of cell surface activation and inhibition |
-
2002
- 2002-04-03 JP JP2002579991A patent/JP2005506524A/ja not_active Withdrawn
- 2002-04-03 US US10/115,718 patent/US20030171271A1/en not_active Abandoned
- 2002-04-03 WO PCT/US2002/010501 patent/WO2002081627A2/en not_active Ceased
- 2002-04-03 EP EP02763922A patent/EP1393075A4/en not_active Withdrawn
- 2002-04-03 CA CA002443378A patent/CA2443378A1/en not_active Abandoned
-
2003
- 2003-10-29 US US10/697,487 patent/US20040126825A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lourbakos et al. | Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis | |
| Phillips et al. | Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover | |
| De Meirleir et al. | A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome | |
| Hortelano et al. | Nitric oxide induces apoptosis via triggering mitochondrial permeability transition | |
| Prescott et al. | Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor‐deficient mice overexpressing MMP‐3, MMP‐12, and MMP‐13 and on restenosis in rats after balloon injury | |
| Thompson et al. | Pathophysiology of abdominal aortic aneurysms: insights from the elastase‐induced model in mice with different genetic backgrounds | |
| Atarashi et al. | Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation–A Report From the J-RHYTHM Registry– | |
| Gendron et al. | TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors | |
| Lee et al. | The involvement of matrix metalloproteinase‐9 in airway inflammation of patients with acute asthma | |
| Hintermann et al. | Discrete proteolysis of focal contact and adherens junction components in Porphyromonas gingivalis-infected oral keratinocytes: a strategy for cell adhesion and migration disabling | |
| Sepper et al. | Human neutrophil collagenase (MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease | |
| Moshal et al. | Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC | |
| EP1575414A4 (en) | METHODS AND DEVICES FOR DETECTION AND THERAPY OF ATHEROMOUS PLAQUES | |
| Death et al. | Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages | |
| Foda et al. | Regulation of gelatinases in human airway smooth muscle cells: mechanism of progelatinase A activation | |
| BR0011130A (pt) | Inibidores de metaloproteases | |
| Martin-Chouly et al. | Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors | |
| DE10346913A1 (de) | Acylhydrazonderivate | |
| JP2005505545A5 (enExample) | ||
| Haraguchi et al. | Porphyromonas gingivalis gingipain is involved in the detachment and aggregation of Aggregatibacter actinomycetemcomitans biofilm | |
| ATE402262T1 (de) | Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden | |
| Maisi et al. | Soluble membrane‐type 1 matrix metalloproteinase (MT1‐MMP) and gelatinase A (MMP‐2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis | |
| Henderson et al. | Collagen I and thrombin activate MMP-2 by MMP-14-dependent and-independent pathways: implications for airway smooth muscle migration | |
| WO2002066981A3 (en) | Monitoring soluble endothelial protein c receptor levels in anticoagulant therapy | |
| IS5851A (is) | Ný lyf til inntöku 5-HT4 gerandefna eða mótlyfja |